ClinicalTrials.gg
CompletedNCT02716779Updated Aug 22, 2016Results posted

Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

A Phase 2 interventional study of Pegylated Interferon (PEG-IFN) alfa-2a and Placebo in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 5 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-08-22.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
54th of 83
68 · median 129
Started
2007
with 9 others
Phase 2
10 of 83
none open now
Registered
78th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 54th largest by enrollment, is one of 10 that started in 2007, is one of 10 in phase 2, and was the 78th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This study examined the influence of ribavirin on the initial virological response in treatment-naïve participants with chronic hepatitis C, genotype 1. Participants were randomized to 1 of 3 treatment groups to receive placebo, ribavirin monotherapy 1000 milligrams (mg) to 1200 mg orally daily depending on body weight or pegylated interferon (PEG-IFN) alfa-2a (Pegasys®) 180 micrograms (mcg) subcutaneously (SC) weekly, for 6 weeks. Following the initial 6 weeks, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin (Copegus®) for 12 weeks. If there was an initial virological response after 12 weeks of combination therapy, treatment could be continued for a further 36 weeks outside of the study.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasians, male or female aged between 18 and 70 years
  • Indication: serological proof of a chronic infection with positive result of anti-Hepatitis C virus (HCV) test and detectable HCV- Ribo Nucleic Acid (RNA) in serum
  • Proven HCV genotype 1 by means of the reverse hybridization assays
  • Proven histological infection activity within the liver with or without proven compensated cirrhosis within the last 24 months prior to start of the study ( degree A)
  • Participants without previous anti-HCV therapy

Exclusion criteria

Exclusion Criteria:

  • Known to interferon or ribavirin or any of the other component parts
  • Pregnant or nursing women, women with child bearing potential and without using a high effective method of . The urine and serum pregnancy test at visit 0 in fertile participants or cohabitants of participants must show a negative result
  • Male partners of pregnant women
  • Infection with genotype 2, 3, 4, 5, or 6
  • Pretreatment with interferon and/or ribavirin
  • participants
  • Treatment of systemic anti-neoplastic or immunomodulatoric medication (including supraphysiological doses of or radiation therapy) within the last 6 months prior to the start of treatment and during the complete time interval of study treatment
  • Chronic hepatitis due to hepatitis C virus (e.g. haemochromatosis, autoimmunohepatitis, metabolic or alcohol-related liver disease)
  • Decompensated liver cirrhosis or liver disease degree B or C or condition after decompensation
  • Signs of a hepatocellular carcinoma within 2 months prior to randomization in case of a cirrhosis or a transition to cirrhosis
  • Ascites or esophagus varices with bleedings as documented in anamnesis
  • Any medical condition that questions in the opinion of the investigator the participant's enrollment and participation in the trial
  • \<13 grams/deciliter (g/dl) in females and \<14 g/dl in males in screening phase
  • Patients with an increased anemia risk (e.g. thalassemia, spherocytosis, etc.) or patients which would be at a particular medical risk in case of an anemia
  • Diagnosed neutropenia \<1.500/microliter (mcl) or thrombocytopenia \<90.000/mcl in screening phase
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Pegylated Interferon (PEG-IFN) alfa-2a

    Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.

    Drug: Pegylated Interferon (PEG-IFN) alfa-2a · Drug: Ribavirin

  • Placebo comparator
    Placebo

    Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.

    Drug: Pegylated Interferon (PEG-IFN) alfa-2a · Drug: Placebo · Drug: Ribavirin

  • Experimental
    Ribavirin

    Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.

    Drug: Pegylated Interferon (PEG-IFN) alfa-2a · Drug: Ribavirin

Interventions

  • Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

    Also known as: Pegasys®

  • DrugPlacebo

    Ribavirin matching placebo orally (PO) twice daily for 6 weeks.

  • Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.

    Also known as: Copegus®

06

What researchers measure

Primary outcomes

  1. Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action

    To investigate possible action mechanisms, three different models were fitted to viruskinetic data and evaluated using related log-likelihood function values. These models were designed assuming individual effects with respect to infectiousness (model 1), virus production (model 2) or degradation of infected cells rate (model 3). The following viruskinetic parameters were fitted in each model: initial viral load, loss rate of infected cells (delta), effectivity of interferon with respect to a pharmacokinetic-pharmacodynamic model. A lower log likelihood function value indicates a lesser fit for the model.

    Time frame: Up to Day 126

Secondary outcomes

  1. Score in Quality of Life Assessed Using Short Form-36 (SF-36) Health Questionnaire

    SF-36 is a psychometric scale to quantify health conditions. This psychometric scale has 8 dimensions of the subjective health status and consists of 36 individual items that have a varying number of related item scores (ranging from "yes/no" up to a 6-point scale). At first the raw scores were determined by summation over all items and weighted accordingly. Afterwards the raw scores were transformed to ranges of 0-100 with 100 being the highest level of health and compared to published reference scales. The following eight dimensions of subjective health conditions were considered: physical functioning index, role physical index, pain, general health perception, vitality, social functioning index, role emotional index and mental health index. The SF36 questionnaire had to be answered by the patients at screening before monotherapy, after monotherapy and at the end of the study (=end of combination therapy).

    Time frame: At screening (Days -56 to -1), at end of monotherapy (Week 6) and at end of combination therapy (Week 18)

  2. Percentage of Participants With Treatment Response

    HCV-RNA level was measured at each visit by a central laboratory. Treatment response was estimated applying the following definitions of response/non-response: 1) Adequate first phase decline: HCV RNA decline ≥ 0.5 log10 International Units/milliliter (IU/mL) from time 0 to 48 hours of PEG-IFN treatment (PEG-IFN arm: day 0 - day 2; placebo and ribavirin arm: day 42-day 44), 2) Rapid virologic response: HCV RNA \< 15 IU/mL (=detection limit) on day 70, 3) Complete early virologic response: HCV RNA \< 15 IU/mL on day 126, 4) Partial early virologic response (log decrease): HCV RNA decrease ≥ 2 log10 IU/mL from day 0 to day 126, 5) Partial early virologic response (cut off): HCV RNA \<30000 IU/mL on day 126, 6) Non-response: HCV RNA decrease \<2 log10 IU/mL from day 0 to day 126, 7) Null-response: HCV RNA decrease \<1 log10 IU/mL from day 0 to day 28 and from day 0 to day 70 for PEG-IFN arm and placebo / ribavirin arm, respectively.

    Time frame: Up to Day 126

  3. Area Under the Concentration-Time Curve (AUC) of Ribavirin

    Evaluation of ribavirin arm after Day 0. Evaluation of placebo and PEG-IFN arms after Day 42.

    Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.

  4. Maximum Concentration (Cmax) of Ribavirin

    Cmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.

    Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.

  5. Time to Maximum Concentration (Tmax) of Ribavirin

    Tmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.

    Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.

  6. Area Under the Concentration-Time Curve (AUC) of PEG-IFN

    Evaluation of PEG-IFN arm after Day 0. Evaluation of ribavirin and placebo arms after Day 42.

    Time frame: From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126

  7. Maximum Concentration (Cmax) of PEG-IFN

    Cmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.

    Time frame: From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126

  8. Time to Maximum Concentration (Tmax) of PEG-IFN

    Tmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.

    Time frame: From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126

  9. Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT)

    Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.

  10. Maximum Concentration (Cmax) of GPT

    Cmax was obtained directly from the concentration-time data.

    Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.

  11. Time to Maximum Concentration (Tmax) of GPT

    Tmax was obtained directly from the concentration-time data.

    Time frame: From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.

07

Results

Posted Jul 14, 2016

Participant flow

Monotherapy
Participant flow — Monotherapy
MilestonePegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Started142627
Completed142526
Not completed011
Withdrew: Adverse event011
Combination Therapy
Participant flow — Combination Therapy
MilestonePegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Started142526
Completed142325
Not completed021
Withdrew: Adverse event021

Outcome measures

PrimaryLog Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action

To investigate possible action mechanisms, three different models were fitted to viruskinetic data and evaluated using related log-likelihood function values. These models were designed assuming individual effects with respect to infectiousness (model 1), virus production (model 2) or degradation of infected cells rate (model 3). The following viruskinetic parameters were fitted in each model: initial viral load, loss rate of infected cells (delta), effectivity of interferon with respect to a pharmacokinetic-pharmacodynamic model. A lower log likelihood function value indicates a lesser fit for the model.

Time frame:
Up to Day 126
Reported as:
Median · log likelihood function value
Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action
log likelihood function valuePegylated Interferon (PEG-IFN) Alfa-2aRibavirinTotal Participant Group
Model 1= infectiousness-27.0 (-34.5 to -14.0)-21.4 (-24.7 to -15.2)-22.2 (-26.0 to -19.3)
Model 2= virus production-28.2 (-35.0 to -14.3)-23.8 (-27.5 to -21.6)-23.9 (-27.4 to -21.6)
Model 3= degradation rate-27.1 (-33.2 to -14.0)-20.7 (-25.5 to -16.0)-23.1 (-26.5 to -18.4)
SecondaryScore in Quality of Life Assessed Using Short Form-36 (SF-36) Health Questionnaire

SF-36 is a psychometric scale to quantify health conditions. This psychometric scale has 8 dimensions of the subjective health status and consists of 36 individual items that have a varying number of related item scores (ranging from "yes/no" up to a 6-point scale). At first the raw scores were determined by summation over all items and weighted accordingly. Afterwards the raw scores were transformed to ranges of 0-100 with 100 being the highest level of health and compared to published reference scales. The following eight dimensions of subjective health conditions were considered: physical functioning index, role physical index, pain, general health perception, vitality, social functioning index, role emotional index and mental health index. The SF36 questionnaire had to be answered by the patients at screening before monotherapy, after monotherapy and at the end of the study (=end of combination therapy).

Time frame:
At screening (Days -56 to -1), at end of monotherapy (Week 6) and at end of combination therapy (Week 18)
Reported as:
Mean · units on a scale
Score in Quality of Life Assessed Using Short Form-36 (SF-36) Health Questionnaire
units on a scalePegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Physical functioning index: Screening95.6 ± 5.276.5 ± 20.279.7 ± 28.7
Physical functioning index: End of monotherapy90.8 ± 9.272.3 ± 28.168.4 ± 27.7
Physical functioning index: End of comb. therapy67.1 ± 20.773.0 ± 14.053.4 ± 31.5
Role physical index: Screening75.0 ± 41.855.6 ± 41.062.5 ± 40.8
Role physical index: End of monotherapy66.7 ± 34.256.8 ± 43.450.5 ± 40.5
Role physical index: End of combination therapy25.0 ± 38.740.0 ± 35.729.7 ± 40.0
Pain: Screening89.3 ± 17.070.3 ± 26.870.0 ± 30.8
Pain: End of monotherapy73.2 ± 23.361.5 ± 27.466.0 ± 29.6
Pain: End of combination therapy72.3 ± 32.256.0 ± 11.860.1 ± 34.8
General health perception: Screening58.6 ± 12.953.6 ± 14.562.9 ± 14.5
General health perception: End of monotherapy58.2 ± 7.659.2 ± 16.954.3 ± 18.0
General health perception: End of comb. therapy60.0 ± 14.355.2 ± 15.047.1 ± 20.6
Vitality: Screening54.2 ± 9.252.8 ± 21.550.9 ± 18.9
Vitality: End of monotherapy45.0 ± 15.244.1 ± 16.341.8 ± 20.1
Vitality: End of combination therapy40.8 ± 14.632.5 ± 12.139.8 ± 16.1
Social functioning index: Screening75.0 ± 23.779.2 ± 24.283.8 ± 20.6
Social functioning index: End of monotherapy72.9 ± 22.968.2 ± 24.080.1 ± 22.6
Social functioning index: End of comb. therapy68.8 ± 23.461.3 ± 19.956.3 ± 25.8
Role emotional index: Screening55.6 ± 50.266.7 ± 50.062.5 ± 43.7
Role emotional index: End of monotherapy55.6 ± 50.269.7 ± 45.853.3 ± 51.6
Role emotional index: End of combination therapy33.3 ± 51.650.0 ± 42.335.4 ± 39.4
Mental health index: Screening68.5 ± 9.163.1 ± 18.164.5 ± 15.4
Mental health index: End of monotherapy61.3 ± 12.362.8 ± 14.061.5 ± 19.7
Mental health index: End of combination therapy72.2 ± 9.061.6 ± 13.247.7 ± 23.0
SecondaryPercentage of Participants With Treatment Response

HCV-RNA level was measured at each visit by a central laboratory. Treatment response was estimated applying the following definitions of response/non-response: 1) Adequate first phase decline: HCV RNA decline ≥ 0.5 log10 International Units/milliliter (IU/mL) from time 0 to 48 hours of PEG-IFN treatment (PEG-IFN arm: day 0 - day 2; placebo and ribavirin arm: day 42-day 44), 2) Rapid virologic response: HCV RNA \< 15 IU/mL (=detection limit) on day 70, 3) Complete early virologic response: HCV RNA \< 15 IU/mL on day 126, 4) Partial early virologic response (log decrease): HCV RNA decrease ≥ 2 log10 IU/mL from day 0 to day 126, 5) Partial early virologic response (cut off): HCV RNA \<30000 IU/mL on day 126, 6) Non-response: HCV RNA decrease \<2 log10 IU/mL from day 0 to day 126, 7) Null-response: HCV RNA decrease \<1 log10 IU/mL from day 0 to day 28 and from day 0 to day 70 for PEG-IFN arm and placebo / ribavirin arm, respectively.

Time frame:
Up to Day 126
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Response
percentage of participantsPegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Adequate first phase decline796572
Rapid virologic response433020
Complete early virologic response644872
Partial early virologic response (log decrease)797884
Partial early virologic response (cut off)797884
Non-response212216
Null responder362612
SecondaryArea Under the Concentration-Time Curve (AUC) of Ribavirin

Evaluation of ribavirin arm after Day 0. Evaluation of placebo and PEG-IFN arms after Day 42.

Time frame:
From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Reported as:
Median · (microgram/milliliter)*day ([mcg/ml]*d)
Area Under the Concentration-Time Curve (AUC) of Ribavirin
(microgram/milliliter)*day ([mcg/ml]*d)Pegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Area Under the Concentration-Time Curve (AUC) of Ribavirin186.6 (142.3 to 201.4)179.4 (142.6 to 203.8)290.1 (257.6 to 370.5)
SecondaryMaximum Concentration (Cmax) of Ribavirin

Cmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.

Time frame:
From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Reported as:
Median · mcg/ml
Maximum Concentration (Cmax) of Ribavirin
mcg/mlPegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Maximum Concentration (Cmax) of Ribavirin2.95 (2.79 to 3.60)2.83 (2.34 to 3.26)3.37 (2.93 to 4.19)
SecondaryTime to Maximum Concentration (Tmax) of Ribavirin

Tmax was obtained directly from the concentration-time data. Evaluation of ribavirin arm after day 0. Evaluation of placebo and PEG-IFN arms after day 42.

Time frame:
From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Reported as:
Median · weeks
Time to Maximum Concentration (Tmax) of Ribavirin
weeksPegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Time to Maximum Concentration (Tmax) of Ribavirin6.0 (4.0 to 12.0)8.0 (6.0 to 12.0)6.4 (6.1 to 8.0)
SecondaryArea Under the Concentration-Time Curve (AUC) of PEG-IFN

Evaluation of PEG-IFN arm after Day 0. Evaluation of ribavirin and placebo arms after Day 42.

Time frame:
From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Reported as:
Median · (nanogram/milliliter)*day ([ng/ml]*d)
Area Under the Concentration-Time Curve (AUC) of PEG-IFN
(nanogram/milliliter)*day ([ng/ml]*d)Pegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Area Under the Concentration-Time Curve (AUC) of PEG-IFN2097.9 (1763.5 to 2997.3)1270.4 (931.8 to 1572.0)1164.9 (925.2 to 1461.3)
SecondaryMaximum Concentration (Cmax) of PEG-IFN

Cmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.

Time frame:
From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Reported as:
Median · ng/ml
Maximum Concentration (Cmax) of PEG-IFN
ng/mlPegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Maximum Concentration (Cmax) of PEG-IFN28.77 (22.80 to 32.38)20.36 (16.92 to 25.83)19.8 (15.80 to 22.30)
SecondaryTime to Maximum Concentration (Tmax) of PEG-IFN

Tmax was obtained directly from the concentration-time data. Evaluation of PEG-IFN arm after day 0. Evaluation of ribavirin and placebo arms after day 42.

Time frame:
From Day 0 at 0 hour (hr), 24 hr, 48 hr and 72 hr, Day 42 at 0 hr and 24 hr and at approximately every other visit up to Day 126
Reported as:
Median · weeks
Time to Maximum Concentration (Tmax) of PEG-IFN
weeksPegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Time to Maximum Concentration (Tmax) of PEG-IFN6.3 (6.1 to 8.0)12.0 (6.0 to 12.0)6.0 (6.0 to 12.0)
SecondaryArea Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT)
Time frame:
From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Reported as:
Median · (Units/liter)*day ([U/L]*d)
Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT)
(Units/liter)*day ([U/L]*d)Pegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT)5078.3 (4358.3 to 6576.5)7233.5 (5337.3 to 8656.3)5231.3 (3917.0 to 5852.5)
SecondaryMaximum Concentration (Cmax) of GPT

Cmax was obtained directly from the concentration-time data.

Time frame:
From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Reported as:
Median · U/L
Maximum Concentration (Cmax) of GPT
U/LPegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Maximum Concentration (Cmax) of GPT68.5 (59.0 to 112.0)88.0 (67.0 to 123.0)75.0 (56.0 to 110.0)
SecondaryTime to Maximum Concentration (Tmax) of GPT

Tmax was obtained directly from the concentration-time data.

Time frame:
From Day 0 at 0 hour (hr), 12 hr, 24 hr, 36 hr, 48 hr, 60 hr and 72 hr, Day 42 at 0 hr, 12 hr, 24 hr and 36 hr and at each visit up to Day 126.
Reported as:
Median · days
Time to Maximum Concentration (Tmax) of GPT
daysPegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirin
Time to Maximum Concentration (Tmax) of GPT2.8 (2.0 to 28.0)14.0 (10.0 to 42.5)3.0 (2.0 to 7.0)

Adverse events

Collected over Up to Day 126. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN Alfa-2a, Period 1 Monotherapy—0/14 (0%)9/14 (64.3%)
Placebo, Period 1 Monotherapy—1/26 (3.8%)9/26 (34.6%)
Ribavirin, Period 1 Monotherapy—0/27 (0%)12/27 (44.4%)
PEG-IFN Alfa-2a, Period 2 Combination Therapy—0/14 (0%)12/14 (85.7%)
Placebo, Period 2 Combination Therapy—2/25 (8%)23/25 (92%)
Ribavirin, Period 2 Combination Therapy—2/26 (7.7%)24/26 (92.3%)
Most frequent serious events
Most frequent serious events
EventPEG-IFN Alfa-2a, Period 1 MonotherapyPlacebo, Period 1 MonotherapyRibavirin, Period 1 MonotherapyPEG-IFN Alfa-2a, Period 2 Combination TherapyPlacebo, Period 2 Combination TherapyRibavirin, Period 2 Combination Therapy
DepressionPsychiatric disorders0/141/260/270/141/250/26
Retinal haemorrhageEye disorders0/140/260/270/141/250/26
Otitis mediaInfections and infestations0/140/260/270/140/251/26
Urinary tract infectionInfections and infestations0/140/260/270/140/251/26
PsychotherapySurgical and medical procedures0/140/260/270/140/251/26
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPEG-IFN Alfa-2a, Period 1 MonotherapyPlacebo, Period 1 MonotherapyRibavirin, Period 1 MonotherapyPEG-IFN Alfa-2a, Period 2 Combination TherapyPlacebo, Period 2 Combination TherapyRibavirin, Period 2 Combination Therapy
HeadacheNervous system disorders2/144/264/272/1410/255/26
FatigueGeneral disorders3/141/264/270/149/256/26
Influenza like illnessGeneral disorders3/140/260/271/145/259/26
NauseaGastrointestinal disorders2/142/261/274/148/255/26
DiarrhoeaGastrointestinal disorders1/140/261/270/145/251/26
ArthralgiaMusculoskeletal and connective tissue disorders0/140/260/270/145/252/26
PruritusSkin and subcutaneous tissue disorders0/140/260/271/145/254/26
DizzinessNervous system disorders0/140/260/270/142/255/26
Decreased appetiteMetabolism and nutrition disorders1/140/261/270/144/253/26
Sleep disorderPsychiatric disorders0/141/262/270/144/252/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirinTotal
Mean45.8 ± 14.448.2 ± 15.450.2 ± 12.948.5 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Pegylated Interferon (PEG-IFN) Alfa-2aPlaceboRibavirinTotal
Female7181742
Male781025
08

Study locations

5 sites
  • Berlin, 13353, Germany
  • Frankfurt Am Main, 60590, Germany
  • Frankfurt Am Main, 60594, Germany
  • Hannover, 30625, Germany
  • Homburg/ Saar, 66424, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2016
First posted
Mar 23, 2016
Start
Apr 2007
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Jul 14, 2016
Last update
Aug 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02716779
Lead sponsor
Hoffmann-La Roche
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Mar 23, 2016
Start date
Apr 2007
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Jul 14, 2016
Last update
Aug 22, 2016

Study contacts

Stephan Zeuzem, Prof. Dr.
principal investigator · Roche Pharma AG, 79639 Grenazch Wyhlen, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion